A5055815043- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- Endometrial and Cervical Cancer Treatments
- Cancer Cells and Metastasis
- Kruppel-like factors research
- Mechanisms of cancer metastasis
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Uterine Myomas and Treatments
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Microtubule and mitosis dynamics
- Gynecological conditions and treatments
- Pelvic floor disorders treatments
- Epigenetics and DNA Methylation
- Endometriosis Research and Treatment
- TGF-β signaling in diseases
- Cancer, Hypoxia, and Metabolism
- Cancer survivorship and care
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- GDF15 and Related Biomarkers
- Renal cell carcinoma treatment
University of Oklahoma Health Sciences Center
2016-2022
ProMedica Toledo Hospital
2021
University of Oklahoma
2016-2018
The Ohio State University
2013-2017
Oklahoma State University Oklahoma City
2016-2017
The Ohio State University Wexner Medical Center
2014
BMI-1, also known as a stem cell factor, is frequently upregulated in several malignancies. Elevated expression of BMI-1 correlates with poor prognosis and therefore considered viable therapeutic target number malignancies including ovarian cancer. Realizing the immense pathologic significance small-molecule inhibitors against are recently being developed. In this study, we functionally characterize PTC-028, an orally bioavailable compound that decreases levels by posttranslational...
With rising incidence rates, endometrial cancer is one of the most common gynecologic malignancies in United States. Although surgery provides significant survival benefit to early-stage patients, those with advanced or recurrent metastatic disease have a dismal prognosis. Limited treatment options include chemotherapy and radiotherapy. Hence, there compelling need for developing molecularly targeted therapy. Here, we show that polycomb ring finger protein BMI1, also known as stem cell...
Objective We assessed the safety and efficacy of administration pegfilgrastim on same day compared with standard 24 to 72 hours after chemotherapy in patients gynecologic malignancies. Methods A retrospective review was conducted undergoing mitigate myelosuppressive consequences chemotherapy. The primary outcome incidence grade 3 4 neutropenia following for same-day (D1) versus (D2+). Secondary outcomes included dose delay, regimen change, hospitalization due neutropenia, febrile...
•Endometriosis associated intestinal tumors are rare, with 5 cases documented.•Endometriosis might present like colorectal carcinoma.•Endometriosis Carcinoma is poor prognosis.
Objectives: Older patients with epithelial ovarian cancer have been shown to a poorer prognosis than younger patients; the SOCRATES study found that older (≥70 years) primary platinum-sensitive (PPSOC) received less treatment and had responses overall survival (OS). This aimed characterize contemporary patterns of care in elderly PPSOC. Methods: Patients receiving at an academic practice diagnosis PPSOC (>6 months platinum-free interval) between January 2000 July 2013 were included....
5569 Background: The safety of the timing pegfilgrastim administration in women with gynecologic malignancies has been questioned. We aimed to assess and efficacy on same day (D1) as chemotherapy compared standard (24-72 hours after chemotherapy) patients malignancies. Methods: A retrospective review was conducted oncology who received mitigate myelosuppressive consequences from January 1, 2002 through July 31, 2012. Data collected included demographics, pathology, blood counts, toxicity,...
<p>PTC-028 inhibits endometrial cancer cell viability</p>
<div>Abstract<p>BMI-1, also known as a stem cell factor, is frequently upregulated in several malignancies. Elevated expression of BMI-1 correlates with poor prognosis and therefore considered viable therapeutic target number malignancies including ovarian cancer. Realizing the immense pathologic significance BMI-1, small-molecule inhibitors against are recently being developed. In this study, we functionally characterize PTC-028, an orally bioavailable compound that decreases...
<div>Abstract<p>With rising incidence rates, endometrial cancer is one of the most common gynecologic malignancies in United States. Although surgery provides significant survival benefit to early-stage patients, those with advanced or recurrent metastatic disease have a dismal prognosis. Limited treatment options include chemotherapy and radiotherapy. Hence, there compelling need for developing molecularly targeted therapy. Here, we show that polycomb ring finger protein BMI1,...
<p>Figure S1: Synthesis of PTC-028; Figure S2: Specificity PTC-028 towards high BMI-1 expressing cells; S3: induces caspase-dependent apoptosis; S4: Pharmacokinetics after a single oral dose either 10 mg/kg or 20mg/kg to CD-1 mice</p>